- Conditions
- NAFLD - Nonalcoholic Fatty Liver Disease
- Interventions
- Losartan potassium, Placebo losartan capsule
- Drug
- Lead sponsor
- National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
- NIH
- Eligibility
- 8 Years to 17 Years
- Enrollment
- 83 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 10
- States / cities
- San Diego, California • San Francisco, California • Atlanta, Georgia + 7 more
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.
These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.
All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1513–1536
of 22,541
matching trials from the live ClinicalTrials.gov search.
- Conditions
- Seizures, Development Delay, Anesthetic Neurotoxicity
- Interventions
- Change in plan of care based on MRI results
- Diagnostic Test
- Lead sponsor
- Baylor College of Medicine
- Other
- Eligibility
- Up to 1095 Days
- Enrollment
- 561 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2017 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Chronic Obstructive Pulmonary Disease
- Interventions
- Verducatib, Placebo matching verducatib
- Drug
- Lead sponsor
- Boehringer Ingelheim
- Industry
- Eligibility
- 40 Years and older
- Enrollment
- 1,800 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2027 – 2029
- U.S. locations
- 18
- States / cities
- Birmingham, Alabama • Phoenix, Arizona • La Palma, California + 14 more
- Conditions
- Clostridium Difficile Infection
- Interventions
- Clostridium difficile vaccine, Placebo
- Biological
- Lead sponsor
- Pfizer
- Industry
- Eligibility
- 50 Years and older
- Enrollment
- 17,535 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2017 – 2021
- U.S. locations
- 220
- States / cities
- Athens, Alabama • Huntsville, Alabama • Mobile, Alabama + 145 more
- Conditions
- Medical Oncology
- Interventions
- BAY1217389, Paclitaxel
- Drug
- Lead sponsor
- Bayer
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 75 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2019
- U.S. locations
- 6
- States / cities
- Santa Monica, California • Denver, Colorado • New Haven, Connecticut + 3 more
- Conditions
- Influenza, Human
- Interventions
- KT07 Capsule, Placebo
- Drug · Other
- Lead sponsor
- Yiling Pharmaceutical Inc.
- Industry
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 391 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2020
- U.S. locations
- 81
- States / cities
- Birmingham, Alabama • Pelham, Alabama • Tolleson, Arizona + 66 more
- Conditions
- Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage IIB Esophageal Adenocarcinoma AJCC v8, Clinical Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Clinical Stage III Esophageal Adenocarcinoma AJCC v8, Clinical Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IC Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IC Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage II Esophageal Adenocarcinoma AJCC v8, Pathologic Stage II Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIB Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage III Esophageal Adenocarcinoma AJCC v8, Pathologic Stage III Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIA Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIA Gastroesophageal Junction Adenocarcinoma AJCC v8, Pathologic Stage IIIB Esophageal Adenocarcinoma AJCC v8, Pathologic Stage IIIB Gastroesophageal Junction Adenocarcinoma AJCC v8
- Interventions
- Atezolizumab, Conventional Surgery, Fluorouracil, Oxaliplatin, Tiragolumab
- Drug · Procedure
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 43 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2026
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Endometriosis-related Pain
- Interventions
- Gefapixant, Placebo, Naproxen
- Drug
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Eligibility
- 18 Years to 49 Years · Female only
- Enrollment
- 187 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2020
- U.S. locations
- 30
- States / cities
- Birmingham, Alabama • Chandler, Arizona • Scottsdale, Arizona + 25 more
- Conditions
- Breast Cancer
- Interventions
- Trastuzumab deruxtecan, Capecitabine, Lapatinib, Trastuzumab
- Drug
- Lead sponsor
- Daiichi Sankyo
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 608 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2025
- U.S. locations
- 41
- States / cities
- Chandler, Arizona • Los Angeles, California • Monterey, California + 34 more
- Conditions
- Acute Myeloid Leukemia, Neutropenia, Infection
- Interventions
- CLT-008, G-CSF
- Biological
- Lead sponsor
- Cellerant Therapeutics
- Industry
- Eligibility
- 55 Years and older
- Enrollment
- 163 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2014 – 2017
- U.S. locations
- 22
- States / cities
- La Jolla, California • Los Angeles, California • San Francisco, California + 16 more
- Conditions
- Acute Promyelocytic Leukemia With t(15;17)(q24.1;q21.2); PML-RARA
- Interventions
- Arsenic Trioxide, Cytarabine, Dexamethasone, Idarubicin, Laboratory Biomarker Analysis, Mitoxantrone Hydrochloride, Quality-of-Life Assessment, Questionnaire Administration, Tretinoin
- Drug · Other
- Lead sponsor
- Children's Oncology Group
- Network
- Eligibility
- 12 Months to 21 Years
- Enrollment
- 158 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015 – 2029
- U.S. locations
- 152
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 121 more
- Conditions
- Breast Cancer
- Interventions
- Lapatinib, Letrozole, Trastuzumab
- Drug
- Lead sponsor
- Baylor Breast Care Center
- Other
- Eligibility
- 18 Years and older · Female only
- Enrollment
- 128 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2011 – 2026
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Chicago, Illinois • Indianapolis, Indiana + 5 more
- Conditions
- Psychosocial Stress
- Interventions
- Therapy dog visitation
- Behavioral
- Lead sponsor
- The University of Texas Health Science Center, Houston
- Other
- Eligibility
- 50 Years and older
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2016 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Heart Decompensation
- Interventions
- Nesiritide, Placebo
- Drug
- Lead sponsor
- Scios, Inc.
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 7,141 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2011
- U.S. locations
- 171
- States / cities
- Huntsville, Alabama • Mobile, Alabama • Anchorage, Alaska + 168 more
- Conditions
- Allergic Rhinitis, Perennial Allergic Rhinitis
- Interventions
- Ciclesonide HFA 80 mcg, Ciclesonide HFA 160 mcg, Placebo
- Drug
- Lead sponsor
- Sumitomo Pharma America, Inc.
- Industry
- Eligibility
- 12 Years and older
- Enrollment
- 1,110 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2009 – 2010
- U.S. locations
- 45
- States / cities
- Huntington Beach, California • Los Angeles, California • Mission Viejo, California + 36 more
- Conditions
- Carcinoma, Squamous Cell
- Interventions
- INGN 201
- Genetic
- Lead sponsor
- Introgen Therapeutics
- Industry
- Eligibility
- 18 Years and older
- Healthy volunteers
- Healthy volunteers not accepted
- U.S. locations
- 8
- States / cities
- Little Rock, Arkansas • Aurora, Colorado • Miami, Florida + 5 more
- Conditions
- Treatment Resistant Depression
- Interventions
- Not listed
- Lead sponsor
- LivaNova
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 138 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 33
- States / cities
- Birmingham, Alabama • Costa Mesa, California • Los Angeles, California + 29 more
- Conditions
- Chronic Rhinosinusitis, Recurrent Acute Rhinosinusitis
- Interventions
- Not listed
- Lead sponsor
- Integra LifeSciences Corporation
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 252 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2015
- U.S. locations
- 25
- States / cities
- Phoenix, Arizona • Los Angeles, California • Sacramento, California + 22 more
- Conditions
- Advanced Malignant Solid Neoplasm, Metastatic Carcinoma in the Liver, Metastatic Carcinoma in the Lung, Metastatic Malignant Neoplasm in the Thoracic Cavity, Metastatic Malignant Solid Neoplasm
- Interventions
- Anti-GITR Agonistic Monoclonal Antibody BMS-986156, Ipilimumab, Nivolumab, Stereotactic Body Radiation Therapy
- Drug · Biological · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2025
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Obesity
- Interventions
- semaglutide 2.4 mg, semaglutide 2.4 mg (placebo)
- Drug
- Lead sponsor
- Novo Nordisk A/S
- Industry
- Eligibility
- Not listed
- Enrollment
- 407 participants
- Healthy volunteers
- Accepts healthy volunteers
- Timeline
- 2021 – 2023
- U.S. locations
- 61
- States / cities
- Montgomery, Alabama • Phoenix, Arizona • Anaheim, California + 52 more
- Conditions
- Cocaine Dependence
- Interventions
- SYN115, PLACEBO
- Drug
- Lead sponsor
- Virginia Commonwealth University
- Other
- Eligibility
- 18 Years to 50 Years
- Enrollment
- 26 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2013
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Acute Coronary Syndrome, Myocardial Infarction
- Interventions
- Elecsys® Troponin T hs Gen 6, Blood sample collection
- Diagnostic Test · Procedure
- Lead sponsor
- Hoffmann-La Roche
- Industry
- Eligibility
- 20 Years and older
- Enrollment
- 5,429 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2024
- U.S. locations
- 26
- States / cities
- El Centro, California • La Jolla, California • Gainesville, Florida + 21 more
- Conditions
- Leukemia, Myelogenous, Chronic
- Interventions
- Nilotinib
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 16 Years and older
- Enrollment
- 148 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2005 – 2018
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Common Bile Duct Neoplasms, Non-Neoplastic Bile Duct Disorder
- Interventions
- AI model classification, DSOC endoscopist experts' classification
- Diagnostic Test
- Lead sponsor
- Instituto Ecuatoriano de Enfermedades Digestivas
- Other
- Eligibility
- 18 Years to 79 Years
- Enrollment
- 170 participants
- Timeline
- 2020 – 2022
- U.S. locations
- 3
- States / cities
- New Brunswick, New Jersey • Houston, Texas